128 related articles for article (PubMed ID: 11595589)
1. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir.
Sund F; Wahlberg J; Eriksson BM
J Clin Virol; 2001 Dec; 23(1-2):107-11. PubMed ID: 11595589
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
Sund F; Tufveson G; Döhler B; Opelz G; Eriksson BM
Nephrol Dial Transplant; 2013 Mar; 28(3):758-65. PubMed ID: 23243043
[TBL] [Abstract][Full Text] [Related]
3. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
4. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R
Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653
[TBL] [Abstract][Full Text] [Related]
6. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
Kacer M; Kielberger L; Bouda M; Reischig T
Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
[TBL] [Abstract][Full Text] [Related]
9. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
[TBL] [Abstract][Full Text] [Related]
10. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study.
Anglicheau D; Lautrette A; Scieux C; Flamant M; Morinet F; Legendre C
Nephrol Dial Transplant; 2003 Aug; 18(8):1654-6. PubMed ID: 12897109
[TBL] [Abstract][Full Text] [Related]
12. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
[TBL] [Abstract][Full Text] [Related]
14. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
Ormrod D; Scott LJ; Perry CM
Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
[TBL] [Abstract][Full Text] [Related]
15. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.
Egan JJ; Carroll KB; Yonan N; Woodcock A; Crisp A
J Heart Lung Transplant; 2002 Apr; 21(4):460-6. PubMed ID: 11927223
[TBL] [Abstract][Full Text] [Related]
16. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
[TBL] [Abstract][Full Text] [Related]
18. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
Kielberger L; Bouda M; Jindra P; Reischig T
Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor.
Mori T; Aisa Y; Shimizu T; Nakazato T; Yamazaki R; Ikeda Y; Okamoto S
Int J Hematol; 2006 Apr; 83(3):266-70. PubMed ID: 16720561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
